EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 37 / Numéro 6-7 (Juin-Juillet 2021) Med Sci (Paris), 37 6-7 (2021) 677-680 Références
Numéro
Med Sci (Paris)
Volume 37, Numéro 6-7, Juin-Juillet 2021
Nos jeunes pousses ont du talent !
Page(s) 677 - 680
Section Partenariat médecine/sciences - Écoles doctorales - Masters
DOI https://doi.org/10.1051/medsci/2021077
Publié en ligne 28 juin 2021
  1. Jiang M, Chen P, Wang L, et al. cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol 2020; 13 : 81. [CrossRef] [PubMed] [Google Scholar]
  2. Motwani M, Pesiridis S, Fitzgerald KA DNA sensing by the cGAS–STING pathway in health and disease. Nat Rev Gene 2019 ; 20 : 657–674. [Google Scholar]
  3. Mackenzie K.J., Carroll P, Martin CA, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 2017 ; 548 : 461–465. [CrossRef] [PubMed] [Google Scholar]
  4. Harding S.M., Benci J.L., Irianto J, et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 2017 ; 548 : 466–470. [CrossRef] [PubMed] [Google Scholar]
  5. Dou Z, Ghosh K, Vizioli MG, et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 2017 ; 550 : 402–406. [CrossRef] [PubMed] [Google Scholar]
  6. Fuertes MB, Kacha AK, Kline J, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J Exp Med 2011 ; 208 : 2005–2016. [CrossRef] [PubMed] [Google Scholar]
  7. Diamond MS, Kinder M, Matsushita H, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011 ; 208 : 1989–2003. [CrossRef] [PubMed] [Google Scholar]
  8. Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014 ; 41 : 843–852. [CrossRef] [PubMed] [Google Scholar]
  9. Marcus A, Mao AJ, Lensink-Vasan M, et al. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity 2018 ; 49 : 754–63 e4. [Google Scholar]
  10. Kwon J, and Bakhoum SF. The Cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov 2020; 10 : 26–39. [CrossRef] [PubMed] [Google Scholar]
  11. Konno H, Yamauchi S, Berglund A, et al. Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. Oncogene 2018 ; 37 : 2037–2051. [CrossRef] [PubMed] [Google Scholar]
  12. Wu S, Zhang Q, Zhang F, et al. HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nat Cell Biol 2019 ; 21 : 1027–1040. [CrossRef] [PubMed] [Google Scholar]
  13. Corrales L, Glickman LH, McWhirter SM, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 2015 ; 11 : 1018–1030. [CrossRef] [PubMed] [Google Scholar]
  14. Demaria O, Gassart AD, Coso S, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci USA 2015 ; 112 : 15408–15413. [Google Scholar]
  15. Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014 ; 41 : 830–842. [CrossRef] [PubMed] [Google Scholar]
  16. Harrington KJ, Brody J, Ingham M, et al. Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas. Ann Oncol 2018; 29 : viii712. [Google Scholar]
  17. Meric-Bernstam F, Sandhu SK, Hamid O, et al. Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. JCO 2019 ; 37 : 2507. [Google Scholar]
  18. Chin EN, Yu C, Vartabedian, VF, et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science 2020; 369 : 993–9. [CrossRef] [PubMed] [Google Scholar]
  19. Pan BS, Perera SA, Piesvaux JA, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 2020; 369 : eaba6098. doi: 10.1126/science.aba6098. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.